DS-1205c
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for DS-1205c, covering 2022-01-11 to 2023-02-08. Get the full timeline:
Most recent: Clinical Trial Update: DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer [Phase 1]